E.M. Pouw

753 total citations
13 papers, 577 citations indexed

About

E.M. Pouw is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Complementary and alternative medicine. According to data from OpenAlex, E.M. Pouw has authored 13 papers receiving a total of 577 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 3 papers in Complementary and alternative medicine. Recurrent topics in E.M. Pouw's work include Lung Cancer Treatments and Mutations (4 papers), Pleural and Pulmonary Diseases (3 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (3 papers). E.M. Pouw is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Pleural and Pulmonary Diseases (3 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (3 papers). E.M. Pouw collaborates with scholars based in Netherlands and United States. E.M. Pouw's co-authors include Annemie M.W.J. Schols, Emiel F.�M. Wouters, Hans Oosting, Mark F. Prummel, Erik Endert, Carolyn M Roos, Veerle Surmont, Rob J. van Klaveren, Nicolaas E.P. Deutz and Ger J. Vusse and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and European Respiratory Journal.

In The Last Decade

E.M. Pouw

13 papers receiving 544 citations

Peers

E.M. Pouw
Priya Agarwala United States
Maria V. Tahamont United States
B. Dalton Australia
A Ellison United States
E.M. Pouw
Citations per year, relative to E.M. Pouw E.M. Pouw (= 1×) peers Toshihiko Hino

Countries citing papers authored by E.M. Pouw

Since Specialization
Citations

This map shows the geographic impact of E.M. Pouw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.M. Pouw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.M. Pouw more than expected).

Fields of papers citing papers by E.M. Pouw

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.M. Pouw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.M. Pouw. The network helps show where E.M. Pouw may publish in the future.

Co-authorship network of co-authors of E.M. Pouw

This figure shows the co-authorship network connecting the top 25 collaborators of E.M. Pouw. A scholar is included among the top collaborators of E.M. Pouw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E.M. Pouw. E.M. Pouw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
2.
Mellema, Wouter W., Egbert F. Smit, Lizza Hendriks, et al.. (2015). Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer. Lung Cancer. 90(2). 249–254. 32 indexed citations
3.
Mellema, Wouter W., Lizza Hendriks, Anthonie J. van der Wekken, et al.. (2014). Retrospective analysis of type of KRAS mutation (mut) and response to first-line platinum-based chemotherapy (PC) in non-small cell lung cancer (NSCLC) patients (pts).. Journal of Clinical Oncology. 32(15_suppl). 8061–8061. 1 indexed citations
4.
Surmont, Veerle, E.M. Pouw, Kimberly‐Anne Tan, et al.. (2009). Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: A non-randomized phase II study. Lung Cancer. 66(3). 333–337. 6 indexed citations
5.
Pouw, E.M., et al.. (2006). Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 1(1). 25–30. 58 indexed citations
6.
Pouw, E.M., et al.. (2006). Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 1(1). 25–30. 37 indexed citations
7.
Toorn, Leon M. van den, et al.. (2005). Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter. Lung Cancer. 50(1). 123–127. 67 indexed citations
8.
Pouw, E.M., et al.. (2005). O-080 Pemetrexed maintenance therapy in patients with malignantpleural mesothelioma. Lung Cancer. 49. S29–S29. 1 indexed citations
9.
Pouw, E.M., et al.. (2000). Early non-elective readmission for chronic obstructive pulmonary disease is associated with weight loss. Clinical Nutrition. 19(2). 95–99. 67 indexed citations
10.
Pouw, E.M., Harry R. Gosker, Gerard Freling, et al.. (2000). Muscle metabolic status in patients with severe COPD with and without long-term prednisolone. European Respiratory Journal. 16(2). 247–247. 25 indexed citations
11.
Pouw, E.M., Annemie M.W.J. Schols, Ger J. Vusse, & Emiel F.�M. Wouters. (1998). Elevated Inosine Monophosphate Levels in Resting Muscle of Patients with Stable Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 157(2). 453–457. 56 indexed citations
12.
Pouw, E.M., Annemie M.W.J. Schols, Nicolaas E.P. Deutz, & Emiel F.�M. Wouters. (1998). Plasma and Muscle Amino Acid Levels in Relation to Resting Energy Expenditure and Inflammation in Stable Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 158(3). 797–801. 93 indexed citations
13.
Pouw, E.M., Mark F. Prummel, Hans Oosting, Carolyn M Roos, & Erik Endert. (1991). Beclomethasone inhalation decreases serum osteocalcin concentrations.. BMJ. 302(6777). 627–628. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026